HK1029330A1 - N-hydroxyformamide derivatives - Google Patents
N-hydroxyformamide derivativesInfo
- Publication number
- HK1029330A1 HK1029330A1 HK00108043A HK00108043A HK1029330A1 HK 1029330 A1 HK1029330 A1 HK 1029330A1 HK 00108043 A HK00108043 A HK 00108043A HK 00108043 A HK00108043 A HK 00108043A HK 1029330 A1 HK1029330 A1 HK 1029330A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptors
- hydroxyformamide derivatives
- tnf
- hydroxyformamide
- derivatives
- Prior art date
Links
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical class ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 abstract 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 abstract 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 abstract 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 abstract 1
- 108010092694 L-Selectin Proteins 0.000 abstract 1
- 102000016551 L-selectin Human genes 0.000 abstract 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9802073.8A GB9802073D0 (en) | 1998-01-30 | 1998-01-30 | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| GBGB9819574.6A GB9819574D0 (en) | 1998-09-08 | 1998-09-08 | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| PCT/GB1999/000313 WO1999038843A1 (en) | 1998-01-30 | 1999-01-29 | Hydroxamic and carboxylic acid derivatives |
| US09/239,603 US6100266A (en) | 1998-01-30 | 1999-01-29 | Hydroxamic and carboxylic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1029330A1 true HK1029330A1 (en) | 2001-03-30 |
Family
ID=27269200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK00108043A HK1029330A1 (en) | 1998-01-30 | 2000-12-14 | N-hydroxyformamide derivatives |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6100266A (pt) |
| EP (1) | EP1051395B1 (pt) |
| JP (1) | JP2002501943A (pt) |
| CN (1) | CN100402496C (pt) |
| AT (1) | ATE346041T1 (pt) |
| AU (1) | AU735929B2 (pt) |
| BR (1) | BR9908215A (pt) |
| CA (1) | CA2317455C (pt) |
| CY (1) | CY1106338T1 (pt) |
| DE (1) | DE69934094T2 (pt) |
| DK (1) | DK1051395T3 (pt) |
| ES (1) | ES2277424T3 (pt) |
| HK (1) | HK1029330A1 (pt) |
| HU (1) | HUP0100597A3 (pt) |
| IL (1) | IL137146A0 (pt) |
| NO (1) | NO326266B1 (pt) |
| PL (1) | PL200418B1 (pt) |
| WO (1) | WO1999038843A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| ES2281346T3 (es) | 1999-06-04 | 2007-10-01 | Astrazeneca Ab | Inhibidores de metaloproteinasas. |
| WO2001047874A1 (en) * | 1999-12-24 | 2001-07-05 | Smithkline Beecham P.L.C. | (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
| CN1247547C (zh) * | 2000-02-21 | 2006-03-29 | 阿斯特拉曾尼卡有限公司 | 作为金属蛋白酶抑制剂的哌啶和哌嗪取代的n－羟基甲酰胺 |
| AU2001232113A1 (en) * | 2000-02-21 | 2001-09-03 | Astrazeneca Ab | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| EP1289980B1 (en) * | 2000-05-25 | 2004-11-17 | Smithkline Beecham Plc | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides |
| FR2827859B1 (fr) * | 2001-07-30 | 2005-09-23 | Lipha | Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete |
| GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| GB0119473D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
| GB0119472D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| JP4219270B2 (ja) | 2001-09-07 | 2009-02-04 | 科研製薬株式会社 | リバースヒドロキサム酸誘導体 |
| GB0128376D0 (en) | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel compounds |
| GB0128378D0 (en) * | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| SE0301922D0 (sv) | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
| JP5199109B2 (ja) * | 2005-11-24 | 2013-05-15 | メルク セローノ ソシエテ アノニム | Ｎ−ヒドロキシアミド誘導体およびその使用 |
| US20100226922A1 (en) * | 2006-06-08 | 2010-09-09 | Dorothea Maetzel | Specific protease inhibitors and their use in cancer therapy |
| US8765814B2 (en) | 2010-07-08 | 2014-07-01 | Kaken Pharmaceutical Co., Ltd. | N-hydroxyformamide derivative and medicament containing same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993021942A2 (en) * | 1992-05-01 | 1993-11-11 | British Biotech Pharmaceuticals Limited | Use of mmp inhibitors |
| ES2184861T3 (es) * | 1995-05-10 | 2003-04-16 | Darwin Discovery Ltd | Compuestos peptidicos inhibidores de la liberacion de la metaloproteinasa y del tnf y su utilizacion terapeutica. |
| KR20000022532A (ko) * | 1996-06-27 | 2000-04-25 | 오노 야꾸힝 고교 가부시키가이샤 | 아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물 |
| US6235928B1 (en) * | 1996-09-27 | 2001-05-22 | Pharmacia & Upjohn Company | β-sulfonyl hydroxamic acids |
| US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| WO1998039316A1 (en) * | 1997-03-04 | 1998-09-11 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| TR199903287T2 (xx) * | 1997-07-31 | 2000-09-21 | Abbott Laboratories | Matriks metaloproteinazlar�n�n ters hidroksamat inhibit�rleri. |
-
1999
- 1999-01-29 PL PL342184A patent/PL200418B1/pl not_active IP Right Cessation
- 1999-01-29 IL IL13714699A patent/IL137146A0/xx active IP Right Grant
- 1999-01-29 JP JP2000530080A patent/JP2002501943A/ja active Pending
- 1999-01-29 HU HU0100597A patent/HUP0100597A3/hu unknown
- 1999-01-29 BR BR9908215-2A patent/BR9908215A/pt not_active Application Discontinuation
- 1999-01-29 DK DK99902703T patent/DK1051395T3/da active
- 1999-01-29 US US09/239,603 patent/US6100266A/en not_active Expired - Fee Related
- 1999-01-29 WO PCT/GB1999/000313 patent/WO1999038843A1/en active IP Right Grant
- 1999-01-29 CA CA2317455A patent/CA2317455C/en not_active Expired - Fee Related
- 1999-01-29 EP EP99902703A patent/EP1051395B1/en not_active Expired - Lifetime
- 1999-01-29 CN CNB998024937A patent/CN100402496C/zh not_active Expired - Fee Related
- 1999-01-29 ES ES99902703T patent/ES2277424T3/es not_active Expired - Lifetime
- 1999-01-29 AT AT99902703T patent/ATE346041T1/de active
- 1999-01-29 DE DE69934094T patent/DE69934094T2/de not_active Expired - Lifetime
- 1999-01-29 AU AU22914/99A patent/AU735929B2/en not_active Ceased
-
2000
- 2000-07-28 NO NO20003868A patent/NO326266B1/no not_active IP Right Cessation
- 2000-12-14 HK HK00108043A patent/HK1029330A1/xx not_active IP Right Cessation
-
2007
- 2007-02-22 CY CY20071100255T patent/CY1106338T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2291499A (en) | 1999-08-16 |
| IL137146A0 (en) | 2001-07-24 |
| US6100266A (en) | 2000-08-08 |
| WO1999038843A1 (en) | 1999-08-05 |
| ATE346041T1 (de) | 2006-12-15 |
| NO326266B1 (no) | 2008-10-27 |
| NO20003868L (no) | 2000-07-28 |
| NO20003868D0 (no) | 2000-07-28 |
| JP2002501943A (ja) | 2002-01-22 |
| AU735929B2 (en) | 2001-07-19 |
| PL200418B1 (pl) | 2009-01-30 |
| HUP0100597A2 (hu) | 2001-08-28 |
| PL342184A1 (en) | 2001-05-21 |
| ES2277424T3 (es) | 2007-07-01 |
| CN100402496C (zh) | 2008-07-16 |
| DE69934094D1 (de) | 2007-01-04 |
| CA2317455A1 (en) | 1999-08-05 |
| CY1106338T1 (el) | 2011-10-12 |
| DK1051395T3 (da) | 2007-04-02 |
| EP1051395A1 (en) | 2000-11-15 |
| HUP0100597A3 (en) | 2001-12-28 |
| EP1051395B1 (en) | 2006-11-22 |
| CN1289322A (zh) | 2001-03-28 |
| BR9908215A (pt) | 2000-11-28 |
| CA2317455C (en) | 2011-01-25 |
| DE69934094T2 (de) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1029330A1 (en) | N-hydroxyformamide derivatives | |
| YU6602A (sh) | Pirimidin-2,4,6-trion metaloproteinazni inhibitori | |
| PL319503A1 (en) | Peptide compounds and their therapeutic application as inhibitors | |
| PL314300A1 (en) | Peptide-type compounds and their therapeutic application as inhibitors of metalloproteinases | |
| UY26981A1 (es) | Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona | |
| EP0863757A4 (pt) | ||
| HK1044718A1 (en) | Unframed gel fraction from psyllium seed husks | |
| PT1119362E (pt) | Metodos de utilizacao de compostos tetraciclina para aumentar a producao de interleucina-10 | |
| MY121294A (en) | Novel hexanoic acid derivatives. | |
| GB0209891D0 (en) | Novel compounds | |
| MY109722A (en) | Azaoxindole derivatives. | |
| ES2192839T3 (es) | Timosina beta 4 oxidada. | |
| DE69723863D1 (de) | Chinoline und deren therapeutische verwendung | |
| HK1040983A1 (en) | Quinones for treatment of diseases. | |
| MY133125A (en) | Novel dihydroxyhexanoic acid derivatives | |
| AU6682594A (en) | Treatment of septic shock | |
| NO954880L (no) | Cytidin deaminase | |
| BR0309996A (pt) | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias | |
| DE69910542D1 (en) | Hydroxamsäure- und carbonsäurederivative | |
| DE60320848D1 (de) | Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen | |
| IT1294932B1 (it) | Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie | |
| NO972906D0 (no) | 4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser | |
| MX9704740A (es) | Monomeros de 3,3-(disustituido)ciclohexan-1-ol y compuestos relacionados. | |
| CL2008002853A1 (es) | Compuestos derivados de piraziin quinolina sustituida, inhibidores de la migracion de macrofagos (mif); y su uso en el tratamiento de inflamacion, shock septico, artritis, cancer, trastornos autoinmunes e inhibicion de angiogenesis (divisional de la solicitud 1088-02) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20120129 |